Developer docs
API playgroundTry for free, no card

Search company profiles

Biohm Technologies

Full company profile

uuid0000x6e

Namestring
Biohm Technologies
Legal namestring
Biohm Health, Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Biohm Technologies is a Cleveland-based microbiome science company that develops clinically validated probiotic, postbiotic, and gut-testing products for dietary supplement brands and health-and-wellness companies. Founded in 2016 by Afif Ghannoum and Dr. Mahmoud Ghannoum — the latter credited with coining the term 'mycobiome' — the company was originally known as Biohm Health, Inc. and sold directly to consumers; in September 2024 it rebranded to Biohm Technologies and refocused on a B2B model, appointing Sam Schatz as CEO. The company's portfolio centers on two proprietary ingredients, Mycohsa (a bacterial-fungal probiotic blend with three completed human clinical trials) and Phorum (a heat-treated postbiotic launched in October 2025), a white-labelable gut microbiome test kit using 16S and ITS sequencing, and the Symbiont discovery platform, which combines proprietary bacterial and fungal datasets, AI/ML developed in partnership with Virginia Tech, and intelligent search across scientific literature to design targeted formulations such as ViviFem (co-developed with ADM for women's health ages 40-65). Biohm monetizes through ingredient supply agreements with supplement manufacturers, white-label test kit partnerships, and co-development arrangements, with the most prominent enterprise relationships being ADM and the Canadian market enabled by Health Canada NPN approval. The company operates an 11-50 employee team from Cleveland headquarters, a research laboratory at Portal Innovations' Science Square campus in Atlanta, and is backed by VTC Ventures, Praesidium, and Sparkfood by Sonae.

Short descriptiontext

Biohm Technologies is a Cleveland-based microbiome company that develops clinically validated probiotic (Mycohsa) and postbiotic (Phorum) ingredients, white-label gut test kits, and the AI-powered Symbiont discovery platform for dietary supplement brands and health-and-wellness companies, with a recent ADM partnership for women's-health formulations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome ingredients, probiotic blends, postbiotic ingredients, gut microbiome testing, nutraceutical biotechnology
Industry3 codes
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Food And Kindred Products2000
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Microbiome Ingredients and Testing
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1B2B Ingredient Sales
TypeLicensing Royalties
Description

Biohm Technologies sells its probiotic blend Mycohsa and postbiotic Phorum as ingredients to dietary supplement brands for use in their products. Ingredients are sold in bulk for formulation into capsules, powders, and chewable tablets. Revenue is generated through ingredient supply agreements with brand partners.

biohmtechnologies.com
2Private Label Testing Services
TypeProfessional Services
Description

Biohm offers white-label gut microbiome test kits to health and wellness brands, providing comprehensive analysis of bacterial and fungal species with branded online portals and personalized reports. Brands can offer these to their customers for engagement and loyalty purposes.

biohmtechnologies.com
3Formulation Development Partnerships
TypeProfessional Services
Description

Co-development agreements with ingredient companies and brands to create targeted microbiome formulations using Biohm's Symbiont platform and dataset, such as the ViviFem partnership with ADM.

biohmtechnologies.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1B2B ingredient pricing for dietary supplement brands
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed. Requires direct inquiry for ingredient quotes (Mycohsa probiotic blend, Phorum postbiotic).

biohmtechnologies.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Mycohsa™
Description

Flagship probiotic blend designed to address both bacterial and fungal communities in the microbiome, clinically proven to break down digestive biofilms. Supported by 3 human clinical trials and 12+ pre-clinical studies.

biohmtechnologies.com
+3 more records
Core offering1 text field

Biohm Technologies is a B2B ingredient and technology supplier that develops, manufactures, and licenses proprietary microbiome ingredients (Mycohsa probiotic blend and Phorum postbiotic) to dietary supplement brands for formulation into finished products. The company also provides white-label gut microbiome test kits to brand partners and operates the Symbiont AI-powered discovery platform for microbiome ingredient development. Its differentiator is the systematic combination of bacterial and fungal (mycobiome) community data, supported by 3 human clinical trials and 12+ pre-clinical studies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Clinically proven to break down digestive biofilms and support optimal levels of both bacteria and yeasts
+3 more records
Product overview1 text field

Biohm Technologies offers a portfolio of microbiome-focused products centered around two core ingredients (Mycohsa™ probiotic and Phorum™ postbiotic), supported by a proprietary gut microbiome test kit platform and the Symbiont® AI-powered discovery platform. Mycohsa and Phorum are B2B ingredient offerings sold to dietary supplement manufacturers, while the gut test kits serve as both a consumer product and white-label solution for brand partners. The Symbiont platform underpins product development by leveraging one of the world's largest microbiome datasets combining bacterial and fungal genetic sequencing. Recent additions include the Longevity Gut Report AI feature and ViviFem (a women's health formulation developed with ADM).

Product and service5 records
1Mycohsa
CategoryProbiotic Ingredient
Description

Flagship probiotic blend combining beneficial bacteria (Lactobacillus acidophilus 16axg, Lacticaseibacillus rhamnosus 18fx, Bifidobacterium breve 19bx) with beneficial fungi (Saccharomyces boulardii 16mxg) and a digestive enzyme (amylase). Clinically proven to break down digestive biofilms and support optimal levels of both bacteria and yeasts. Sold as a B2B ingredient to dietary supplement brands for formulation into capsules, powders, and chewable tablets.

2Phorum
CategoryPostbiotic Ingredient
Description

Next-generation postbiotic ingredient developed from heat-treated bacterial and fungal strains (Lactobacillus acidophilus 16axg, Lacticaseibacillus rhamnosus 18fx, Saccharomyces boulardii), delivering stable bioactive compounds including cell wall fragments, enzymes, peptides, and organic acids without requiring live organisms. Designed to support healthy immune function. Sold as a B2B ingredient to dietary supplement brands.

3Gut Microbiome Test Kits
CategoryMicrobiome Testing Service
Description

At-home gut microbiome test kits analyzing both fungal and bacterial species in the gut using 16S and ITS sequencing methods. Provides a proprietary Gut Score across four criteria (Microbiome Diversity, Phyla Balance, Beneficial Species, Pathogenic Species), personalized diet and lifestyle recommendations, and actionable insights. Available directly to consumers and as a private label solution for brand partners for consumer engagement and loyalty.

4Symbiont Discovery Platform
CategoryDiscovery Platform / Formulation Services
Description

Biohm's systematic approach to ingredient discovery, selection, and formulation, leveraging one of the world's largest microbiome datasets. Combines bacterial and fungal genetic sequencing with over 50 metadata points and AI/machine learning algorithms (via Virginia Tech partnership) to identify biomarkers and optimal ingredients for target demographics. Validated and published in Gastroenterology. Used by Biohm and partners such as ADM to co-develop targeted microbiome formulations.

5ViviFem
CategoryWomen's Health Microbiome Formulation
Description

Data-driven, targeted microbiome formulation for women aged 40-65, developed in partnership with ADM. Combines pre-, pro-, and postbiotics including Mycohsa probiotic blend, PreforPro prebiotic, and ES1 postbiotic, supported by seven published human clinical trials and dozens of pre-clinical studies. Designed to address microbiome misalignments in aging women.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Biohm opened its new 33,000-square-foot research laboratory at Portal Innovations' Science Square campus in Atlanta. The facility provides access to shared infrastructure, $2M+ in equipment, and BSL-2 capability, enabling Biohm to focus capital on people and research rather than infrastructure buildout.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-15
Description

Joint development of ViviFem, a targeted microbiome formulation for women's health ages 40-65. ADM employed Biohm's Symbiont platform to create a combination of pre-, pro-, and postbiotics addressing microbiome misalignments in aging women. The formulation includes Mycohsa, PreforPro, and ES1. Seven published human clinical trials and dozens of pre-clinical studies support the ingredients.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-03-07
Description

Strategic partnership to enhance Symbiont platform through AI/ML technology development. Virginia Tech researchers developing predictors using machine learning algorithms to link microbial populations to phenotypes for biomarker identification. Dan Sui, Senior Vice President for Research and Innovation at Virginia Tech, emphasized importance of industry-university collaboration for innovation. Brian Mixer noted VTC Ventures' thesis of leveraging Virginia Tech's research capabilities.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novozymes (merged into Novonesis) is a global enzyme and microbiome technology platform serving food, health, and industrial markets. Comparable in microbiome-adjacent science and ingredient supply scale, though broader in scope.

TypeEmerging player
Description

Deerland is a U.S. probiotic and enzyme ingredient supplier now owned by ADM and a Biohm partner. Comparable in the B2B probiotic/prebiotic ingredient space, though its portfolio is bacterial-focused versus Biohm's bacterial-fungal thesis.

3BioGaia
TypeBroad incumbent
Description

BioGaia is a long-established Swedish probiotic ingredient company supplying L. reuteri strains to supplement and infant formula brands globally. Comparable to Biohm as a science-backed B2B probiotic ingredient supplier, but much larger and bacterial-only focused.

TypeDirect peer
Description

Viome sells at-home gut microbiome test kits combined with personalized nutrition/supplement recommendations. Comparable to Biohm on the consumer-facing test + insights side, though Viome is consumer-direct rather than B2B.

TypeDirect peer
Description

Pendulum develops targeted probiotic formulations backed by clinical trials for specific health conditions (metabolic health). Highly comparable to Biohm's Mycohsa approach of clinically validated, condition-specific microbiome interventions.

TypeOthers
Description

ADM is Biohm's largest enterprise partner and acquired Deerland Probiotics & Enzymes. Comparable as a customer/distributor for microbiome ingredients and as a potential acquirer of microbiome IP, though its core business is broad agricultural commodity processing.

TypeDirect peer
Description

Seed Health develops science-backed probiotic and prebiotic formulations with proprietary microbiome science, including bacterial-fungal considerations. Comparable to Biohm as a science-led microbiome ingredient company with consumer and partner offerings.

TypeBroad incumbent
Description

Chr. Hansen (now part of Novonesis) is one of the world's largest producers of probiotic bacterial cultures for supplement, dairy, and infant nutrition applications. Comparable as a B2B microbiome ingredient incumbent but operates at industrial scale and lacks a fungal/mycobiome thesis.

TypeDirect peer
Description

Zoe combines gut microbiome testing with personalized nutrition scoring and recommendations. Directly comparable to Biohm's gut test kit + personalized insights offering, though Zoe is consumer-direct and primarily UK/US focused.

TypeDirect peer
Description

Sun Genomics offers personalized probiotic formulations based on individual gut microbiome testing results. Comparable to Biohm in combining microbiome sequencing with custom-formulated biotic products.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biohm Technologies

Microbiome Ingredients and Testingbiohmtechnologies.com

Biohm Technologies is a Cleveland-based microbiome company that develops clinically validated probiotic (Mycohsa) and postbiotic (Phorum) ingredients, white-label gut test kits, and the AI-powered Symbiont discovery platform for dietary supplement brands and health-and-wellness companies, with a recent ADM partnership for women's-health formulations.

What Biohm Technologies does

Biohm Technologies is a Cleveland-based microbiome science company that develops clinically validated probiotic, postbiotic, and gut-testing products for dietary supplement brands and health-and-wellness companies. Founded in 2016 by Afif Ghannoum and Dr. Mahmoud Ghannoum — the latter credited with coining the term 'mycobiome' — the company was originally known as Biohm Health, Inc. and sold directly to consumers; in September 2024 it rebranded to Biohm Technologies and refocused on a B2B model, appointing Sam Schatz as CEO. The company's portfolio centers on two proprietary ingredients, Mycohsa (a bacterial-fungal probiotic blend with three completed human clinical trials) and Phorum (a heat-treated postbiotic launched in October 2025), a white-labelable gut microbiome test kit using 16S and ITS sequencing, and the Symbiont discovery platform, which combines proprietary bacterial and fungal datasets, AI/ML developed in partnership with Virginia Tech, and intelligent search across scientific literature to design targeted formulations such as ViviFem (co-developed with ADM for women's health ages 40-65). Biohm monetizes through ingredient supply agreements with supplement manufacturers, white-label test kit partnerships, and co-development arrangements, with the most prominent enterprise relationships being ADM and the Canadian market enabled by Health Canada NPN approval. The company operates an 11-50 employee team from Cleveland headquarters, a research laboratory at Portal Innovations' Science Square campus in Atlanta, and is backed by VTC Ventures, Praesidium, and Sparkfood by Sonae.

Biohm Technologies firmographics

Firmographics
Name
Biohm Technologies
Legal name
Biohm Health, Inc.
Website
https://biohmtechnologies.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Biohm Technologies is a Cleveland-based microbiome company that develops clinically validated probiotic (Mycohsa) and postbiotic (Phorum) ingredients, white-label gut test kits, and the AI-powered Symbiont discovery platform for dietary supplement brands and health-and-wellness companies, with a recent ADM partnership for women's-health formulations.
Ownership category
akta.pro rank

Biohm Technologies industry classification

Industry
Product category
Microbiome Ingredients and Testing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Food And Kindred Products (2000), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms

Keywords

  • Microbiome ingredients
  • Probiotic blends
  • Postbiotic ingredients
  • Gut microbiome testing
  • Nutraceutical biotechnology

Where Biohm Technologies is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Biohm Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. B2B Ingredient Sales: Biohm Technologies sells its probiotic blend Mycohsa and postbiotic Phorum as ingredients to dietary supplement brands for use in their products. Ingredients are sold in bulk for formulation into capsules, powders, and chewable tablets. Revenue is generated through ingredient supply agreements with brand partners.
  2. Private Label Testing Services: Biohm offers white-label gut microbiome test kits to health and wellness brands, providing comprehensive analysis of bacterial and fungal species with branded online portals and personalized reports. Brands can offer these to their customers for engagement and loyalty purposes.
  3. Formulation Development Partnerships: Co-development agreements with ingredient companies and brands to create targeted microbiome formulations using Biohm's Symbiont platform and dataset, such as the ViviFem partnership with ADM.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B ingredient pricing for dietary supplement brands

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Biohm Technologies product offering

Product offering

Core offering

Biohm Technologies is a B2B ingredient and technology supplier that develops, manufactures, and licenses proprietary microbiome ingredients (Mycohsa probiotic blend and Phorum postbiotic) to dietary supplement brands for formulation into finished products. The company also provides white-label gut microbiome test kits to brand partners and operates the Symbiont AI-powered discovery platform for microbiome ingredient development. Its differentiator is the systematic combination of bacterial and fungal (mycobiome) community data, supported by 3 human clinical trials and 12+ pre-clinical studies.

Product overview

Biohm Technologies offers a portfolio of microbiome-focused products centered around two core ingredients (Mycohsa™ probiotic and Phorum™ postbiotic), supported by a proprietary gut microbiome test kit platform and the Symbiont® AI-powered discovery platform. Mycohsa and Phorum are B2B ingredient offerings sold to dietary supplement manufacturers, while the gut test kits serve as both a consumer product and white-label solution for brand partners. The Symbiont platform underpins product development by leveraging one of the world's largest microbiome datasets combining bacterial and fungal genetic sequencing. Recent additions include the Longevity Gut Report AI feature and ViviFem (a women's health formulation developed with ADM).

Differentiator

Problem solved

Functional benefit

Brands

  • Mycohsa™: Flagship probiotic blend designed to address both bacterial and fungal communities in the microbiome, clinically proven to break down digestive biofilms. Supported by 3 human clinical trials and 12+ pre-clinical studies.
  • Phorum™
  • Symbiont®
  • ViviFem™

Products and services

  • Mycohsa Flagship probiotic blend combining beneficial bacteria (Lactobacillus acidophilus 16axg, Lacticaseibacillus rhamnosus 18fx, Bifidobacterium breve 19bx) with beneficial fungi (Saccharomyces boulardii 16mxg) and a digestive enzyme (amylase). Clinically proven to break down digestive biofilms and support optimal levels of both bacteria and yeasts. Sold as a B2B ingredient to dietary supplement brands for formulation into capsules, powders, and chewable tablets.
  • Phorum Next-generation postbiotic ingredient developed from heat-treated bacterial and fungal strains (Lactobacillus acidophilus 16axg, Lacticaseibacillus rhamnosus 18fx, Saccharomyces boulardii), delivering stable bioactive compounds including cell wall fragments, enzymes, peptides, and organic acids without requiring live organisms. Designed to support healthy immune function. Sold as a B2B ingredient to dietary supplement brands.
  • Gut Microbiome Test Kits At-home gut microbiome test kits analyzing both fungal and bacterial species in the gut using 16S and ITS sequencing methods. Provides a proprietary Gut Score across four criteria (Microbiome Diversity, Phyla Balance, Beneficial Species, Pathogenic Species), personalized diet and lifestyle recommendations, and actionable insights. Available directly to consumers and as a private label solution for brand partners for consumer engagement and loyalty.
  • Symbiont Discovery Platform Biohm's systematic approach to ingredient discovery, selection, and formulation, leveraging one of the world's largest microbiome datasets. Combines bacterial and fungal genetic sequencing with over 50 metadata points and AI/machine learning algorithms (via Virginia Tech partnership) to identify biomarkers and optimal ingredients for target demographics. Validated and published in Gastroenterology. Used by Biohm and partners such as ADM to co-develop targeted microbiome formulations.
  • ViviFem Data-driven, targeted microbiome formulation for women aged 40-65, developed in partnership with ADM. Combines pre-, pro-, and postbiotics including Mycohsa probiotic blend, PreforPro prebiotic, and ES1 postbiotic, supported by seven published human clinical trials and dozens of pre-clinical studies. Designed to address microbiome misalignments in aging women.

Quantifiable outcome

  • Clinically proven to break down digestive biofilms and support optimal levels of both bacteria and yeasts
  • +3 more outcomes

Companies that use Biohm Technologies

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Biohm Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Biohm Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • Portal InnovationsmajorStrategic or Co-development Partner · 5 November 2025Biohm opened its new 33,000-square-foot research laboratory at Portal Innovations' Science Square campus in Atlanta. The facility provides access to shared infrastructure, $2M+ in equipment, and BSL-2 capability, enabling Biohm to focus capital on people and research rather than infrastructure buildout.
  • ADM (Archer Daniels Midland)coreStrategic or Co-development Partner · 15 October 2024Joint development of ViviFem, a targeted microbiome formulation for women's health ages 40-65. ADM employed Biohm's Symbiont platform to create a combination of pre-, pro-, and postbiotics addressing microbiome misalignments in aging women. The formulation includes Mycohsa, PreforPro, and ES1. Seven published human clinical trials and dozens of pre-clinical studies support the ingredients.
  • Virginia TechcoreTechnology or Integration · 7 March 2024Strategic partnership to enhance Symbiont platform through AI/ML technology development. Virginia Tech researchers developing predictors using machine learning algorithms to link microbial populations to phenotypes for biomarker identification. Dan Sui, Senior Vice President for Research and Innovation at Virginia Tech, emphasized importance of industry-university collaboration for innovation. Brian Mixer noted VTC Ventures' thesis of leveraging Virginia Tech's research capabilities.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Biohm Technologies competitors and assessment

Company assessment

Broad incumbents

  • Novozymes (Novonesis): Novozymes (merged into Novonesis) is a global enzyme and microbiome technology platform serving food, health, and industrial markets. Comparable in microbiome-adjacent science and ingredient supply scale, though broader in scope.
  • BioGaia: BioGaia is a long-established Swedish probiotic ingredient company supplying L. reuteri strains to supplement and infant formula brands globally. Comparable to Biohm as a science-backed B2B probiotic ingredient supplier, but much larger and bacterial-only focused.
  • Chr. Hansen (Novonesis): Chr. Hansen (now part of Novonesis) is one of the world's largest producers of probiotic bacterial cultures for supplement, dairy, and infant nutrition applications. Comparable as a B2B microbiome ingredient incumbent but operates at industrial scale and lacks a fungal/mycobiome thesis.

Emerging players

  • Deerland Probiotics & Enzymes: Deerland is a U.S. probiotic and enzyme ingredient supplier now owned by ADM and a Biohm partner. Comparable in the B2B probiotic/prebiotic ingredient space, though its portfolio is bacterial-focused versus Biohm's bacterial-fungal thesis.

Direct peers

  • Viome: Viome sells at-home gut microbiome test kits combined with personalized nutrition/supplement recommendations. Comparable to Biohm on the consumer-facing test + insights side, though Viome is consumer-direct rather than B2B.
  • Pendulum Therapeutics: Pendulum develops targeted probiotic formulations backed by clinical trials for specific health conditions (metabolic health). Highly comparable to Biohm's Mycohsa approach of clinically validated, condition-specific microbiome interventions.
  • Seed Health: Seed Health develops science-backed probiotic and prebiotic formulations with proprietary microbiome science, including bacterial-fungal considerations. Comparable to Biohm as a science-led microbiome ingredient company with consumer and partner offerings.
  • Zoe: Zoe combines gut microbiome testing with personalized nutrition scoring and recommendations. Directly comparable to Biohm's gut test kit + personalized insights offering, though Zoe is consumer-direct and primarily UK/US focused.
  • Sun Genomics: Sun Genomics offers personalized probiotic formulations based on individual gut microbiome testing results. Comparable to Biohm in combining microbiome sequencing with custom-formulated biotic products.

Others

  • ADM: ADM is Biohm's largest enterprise partner and acquired Deerland Probiotics & Enzymes. Comparable as a customer/distributor for microbiome ingredients and as a potential acquirer of microbiome IP, though its core business is broad agricultural commodity processing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Biohm Technologies social profiles

Digital presence

Biohm Technologies compliance and trust

Trust signal

Compliance4 records

Biohm Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biohm Technologies leadership team

Management profile

Number of profiles

Profiles7 records

Biohm Technologies funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biohm Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biohm Technologies

What does Biohm Technologies do?

Biohm Technologies is a B2B ingredient and technology supplier that develops, manufactures, and licenses proprietary microbiome ingredients (Mycohsa probiotic blend and Phorum postbiotic) to dietary supplement brands for formulation into finished products. The company also provides white-label gut microbiome test kits to brand partners and operates the Symbiont AI-powered discovery platform for microbiome ingredient development. Its differentiator is the systematic combination of bacterial and fungal (mycobiome) community data, supported by 3 human clinical trials and 12+ pre-clinical studies.

Is Biohm Technologies a public or private company?

Biohm Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biohm Technologies founded?

Biohm Technologies was founded in 2016. It employs 11 to 50 people.

Where is Biohm Technologies based?

Biohm Technologies is headquartered in Cleveland, United States, in the North America region.

How does Biohm Technologies make money?

Three revenue lines are on record. B2B Ingredient Sales are the primary driver. The others are private Label Testing Services and formulation Development Partnerships.

Who are Biohm Technologies's main competitors?

Broad incumbents on record are Novozymes (Novonesis), BioGaia and Chr. Hansen (Novonesis). Deerland Probiotics & Enzymes is listed as an emerging player. Direct peers are Viome, Pendulum Therapeutics, Seed Health, Zoe and Sun Genomics. ADM is listed as an others.

Does Biohm Technologies have an API?

No public API is recorded for Biohm Technologies.

What industry is Biohm Technologies in?

Biohm Technologies's product category is Microbiome Ingredients and Testing. Its primary akta.pro industry code is HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery), with a secondary code of HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal). Its NAICS code is 325414 and its SIC code is 2000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ChaindrugreviewCRN announces lineup for Innovation Exchange emerging supplement science showcaseThe Council for Responsible Nutrition (CRN) announced the lineup for its Innovation Exchange event, scheduled for October 6–8, 2026 at the Westin Carlsbad Resort & Spa in Carlsbad, California. The showcase features emerging science and technologies in dietary supplements and functional foods, with presentations spanning women's health, microbiome science, metabolic wellness, sports nutrition, and ingredient innovation. A steering committee including representatives from Better Being Co., GNC Holdings, Kenvue/Zarbee's, Nature's Way, and the Unilever Wellbeing Collective selected presentations from companies including Balchem Nutrition, Biohm Technologies, dsm-firmenich, Kaneka Probiotics, Nutriventia Private Limited, Probi, and Specialty Enzymes & Probiotics.nutritioninsight.comHealth Canada greenlights Biohm Technologies’ probiotic and fungal blend for gut healthHealth Canada has granted a Natural Product Number to Biohm Technologies’ Mycohsa, a probiotic blend combining bacterial and fungal strains for digestive health. This regulatory approval allows Canadian supplement brands to use the ingredient with pre-approved structure/function claims, streamlining product development. The milestone provides Biohm Technologies with enhanced flexibility and confidence for its partners in the Canadian market.GlobeNewswireMicrobiome Sample Preparation Technology Market Research Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031The Global Microbiome Sample Preparation Technology Market is projected to grow from USD 0.25 billion in 2025 to USD 0.37 billion by 2031, reflecting a compound annual growth rate of 6.75%. The market's expansion is driven by rising chronic disease incidence, personalized medicine demand, and increased investment in biotechnology research, as exemplified by Biohm Technologies' $4.52 million Series B funding in April 2025 and Qiagen's November 2024 collaboration with McGill University for low-biomass sample methods. However, the industry faces significant challenges due to the absence of universal standardization for sample collection and processing protocols, which undermines data reproducibility and impedes regulatory validation and commercialization efforts.Nutraceutical Business ReviewBiohm Technologies secures Health Canada NPN for Mycohsa probiotic blendBiohm Technologies has announced that its probiotic blend, Mycohsa, has received a Natural Product Number (NPN) from Health Canada. This approval allows supplement firms in Canada to market products using Mycohsa and benefit from streamlined product development and registration processes. The approval is seen as a significant milestone for Biohm Technologies and its partners in Canada.RdworldonlineInside Biohm’s new microbiome lab at Atlanta’s Science SquareBiohm Technologies, a Cleveland-based microbiome company focused on dietary supplements, has opened a new research lab at Portal Innovations' Atlanta site within Science Square Labs, extending its R&D footprint beyond its Case Western Reserve base. The 33,000-square-foot facility gives the company access to over 100 shared benches, more than $2 million in equipment, and BSL-2 capability, allowing it to focus capital on people and research rather than infrastructure buildout. The lab will support strain development, characterization, and product-focused studies of bacterial-fungal interactions in the gut, feeding into Biohm's Symbiont discovery platform that underpins probiotic products such as Mycohsa.PrwebBiohm Technologies Expands Biotech R&D Footprint with New Lab Space at Portal Innovations in AtlantaBiohm Technologies, a Cleveland-based microbiome innovation company, has opened laboratory space at Portal Innovations in Atlanta's Science Square, marking a strategic expansion of its R&D footprint to accelerate development of next-generation microbiome ingredients. The new facility, situated within Atlanta's growing life-science hub near Georgia Tech, will focus on strain development and product-focused research on bacterial-fungal interactions in the gut microbiome to support dietary supplement innovation. The company says the expansion reflects its commitment to advancing gut microbiome science and bringing new innovation to the natural products industry faster.BiohmtechnologiesBiohm® Technologies Secures New Funding and Strengthens Scientific LeadershipBiohm Technologies announced new institutional investors, including Praesidium and Sparkfood by Sonae, in its latest financing round. The company also appointed Dr. John Deaton as Vice President of Science and Technology, bringing over 17 years of microbial research experience. The funding and leadership appointment support Biohm's expansion of microbiome technology solutions.NutraceuticalsworldBiohm Technologies Launches Gut Microbiome Test Kit with AI-Powered Longevity AnalysisBiohm Technologies announced the launch of a Longevity Gut Report feature within its gut microbiome test kits, using AI and bioinformatics to analyze how an individual's gut microbiome may influence the aging process. The company's bioinformatics team identified key bacterial and fungal taxa through machine learning and deep learning techniques trained on more than 10 million data points, creating a model that identifies approximately 100 key taxa involved in aging. The feature provides personalized insights tailored to each individual, representing a new tool in personalized health and wellness.Nutraceutical Business ReviewBiohm Technologies enhances its microbiome gut test kit with AI-powered longevity analysisBiohm Technologies has launched a new Longevity Gut Report that uses AI, machine learning, and deep learning techniques trained on over 10 million data points to identify approximately 100 key bacterial and fungal taxa involved in the ageing process. The feature provides personalized insights into how an individual's gut microbiome may influence longevity, combining advanced neural networks with scientific literature review and clinician collaboration. The company says this enhancement represents a step forward in personalized health and wellness while offering health & wellness brands an opportunity to engage consumers and foster customer loyalty.